You just read:

Southeast Asia Atopic Dermatitis Therapeutics Markets to 2024 - How will Novel IL-4Ra Inhibitor Therapy Dupixent, which Holds First-to-Market Advantage, Contribute to Growth

News provided by

Research and Markets

Jan 15, 2019, 09:15 ET